Cardiolynx Receives Patent on Improved Angina Pectoris Drug
The Cardiolynx technology employs specific vasodilating chemical linkers as grafts onto or in combination with established cardiovascular drugs resulting in a dual mode of action: the original mode of action of the established product plus the synergistic vasodilative mode.
Dr. Dirk Sartor, CEO of Cardiolynx, commented: "CLC-1280 is active in preclinical models of vasodilatation and has the potential to reduce blood pressure and prevent or reduce angina pectoris thus improving the standard care of this chronic and debilitating condition. The new patent strengthens Cardiolynx's intellectual property portfolio which includes four patent families with pending applications worldwide."
Original publication
Knorr M et al.: "Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol."; Pharmacology 2012; 90: 193-204.
Original publication
Knorr M et al.: "Characterization of new organic nitrate hybrid drugs covalently bound to valsartan and cilostazol."; Pharmacology 2012; 90: 193-204.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.